Archive · 12 Nov 2025
Shaily Engineering Plastics Stock Poised for Growth, Analysts Project Rs 3,000 Target
Imagine a company that makes plastic parts for factories and also special parts for medicines.
Some smart investors and analysts think this company's stock, which is like a share of ownership, will become much more valuable.
They believe it will grow a lot because it has new, special products for delivering medicines and is getting ready to make more of them.
They are also expanding how much they can produce, like adding more machines to make things faster.
This company's stock has already grown a lot in the past.
However, there's a chance that the new medicine products might not become popular as quickly as expected, or that other companies might sell similar products for cheaper prices.
Despite these possible problems, the analysts are still very positive and have set a goal for how high the stock price might go.
Shaily Engineering Plastics' stock is projected by Systematix Institutional Equities to reach Rs 3,000 in a year, representing over 20% growth.
Growth is expected to be driven by the company's drug-delivery portfolio and the global GLP-1 opportunity.
The company is expanding its pen production capacity, planning to double it by FY26 end.
Renowned investor Ashish Kacholia holds a 3.22% stake in Shaily Engineering Plastics.
Key risks include slower market acceptance for GLP-1 products and potential delays in regulatory approvals for generics.
- Who
- Shaily Engineering Plastics, a manufacturer of industrial plastic and other materials, and investor Ashish Kacholia.
- What
- Shaily Engineering Plastics' stock is projected by analysts to reach Rs 3,000 in a year due to its drug-delivery portfolio and GLP-1 opportunity, with capacity expansion underway. Investors are optimistic about its growth prospects.
- When
- The price target is set for one year; Q2 results and September 2025 quarter holdings are noted.
- Where
- India (based on typical stock market reporting context).
- Why
- Projected growth is driven by a differentiated, IP-backed drug-delivery portfolio, the global GLP-1 opportunity, capacity expansions, and a favorable shift in product mix towards proprietary platforms.
Analyst Optimism
Potential Risks
Growth Drivers
Analyst Optimism
Systematix Institutional Equities anticipates significant growth driven by a differentiated, IP-backed drug-delivery portfolio and the accelerating global GLP-1 opportunity, coupled with capacity expansion in pens.
Potential Risks
Slower market acceptance of GLP-1 products in emerging markets could delay ramp-up, and generics in regulated markets might face delays due to regulatory approvals or intense price competition from innovators.
Revenue Projections
Analyst Optimism
The brokerage models a 28.5% topline CAGR over FY25-27E, with Healthcare expected to grow at 68.1% CAGR, Consumer business at 13.2%, and Industrial at 37%.
Potential Risks
The actual growth may be hampered if the projected ramp-up for GLP-1 products and generics in regulated markets does not materialize as anticipated.
- Company Name
- Shaily Engineering Plastics
- Business
- Manufacturer of industrial plastic and other materials, customized components.
- Analyst Target Price
- Rs 3,034
- Projected Timeframe
- One year
- Ashish Kacholia's Stake
- 3.22% (14.78 lakh shares) as of September 2025 quarter
- Capacity Expansion
- Doubling pen capacity from 40mn to 80mn units by FY26 end (Capex Rs 1,250 mn)
- Q2 Revenue Growth
- 14% increase to Rs 246 crore
- Q2 Net Profit Growth
- 26.84% increase to Rs 52.55 crore